{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034247","form_type":"8-K","ticker":null,"cik":"0001662244","company_name":"Cyteir Therapeutics, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.019176+00:00","generated_at":"2026-06-04T11:45:30.666079+00:00","sec_items":["1.02","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cyteir Therapeutics files certificate of dissolution; estimates $3.10-$3.16 per share liquidation distribution","bullets":["Filed Certificate of Dissolution with Delaware Secretary of State on March 20, 2024, dissolving the company.","Record date set as March 20, 2024 for liquidation distributions; stock transfer books closed immediately.","Estimated aggregate cash distribution between $3.10 and $3.16 per share, with first payment expected in Q2 2024.","Terminated Amended and Restated 2012 Stock Incentive Plan, 2021 Equity Incentive Plan, and Employee Stock Purchase Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034247","json":"https://secwatch.observer/filing/0000950170-24-034247.json","markdown":"https://secwatch.observer/filing/0000950170-24-034247.md","text":"https://secwatch.observer/filing/0000950170-24-034247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662244/000095017024034247/0000950170-24-034247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662244/000095017024034247/cyt-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:45:30.666079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8137ed56831bd03b2c25f7ce896b441b347b46a2","claim":"Cyteir Therapeutics, Inc. terminated Amended and Restated 2012 Stock Incentive Plan valued at terminated.","evidence_excerpt":"Item 1.02 Termination of Material Definitive Agreement Immediately following the filing of the Certificate of Dissolution (as defined below) with the Secretary of State of the State of Delaware, Cyteir Therapeutics, Inc. (the “Company”) terminated the Company’s Amended and Restated 2012 Stock Incentive Plan, the Company’s 2021 Equity Incentive Plan and the Company’s 2021 Employee Stock Purchase Plan.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662244/000095017024034247/0000950170-24-034247-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"equity purchase"},{"label":"Value","value":"terminated"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}